Sociedade Portuguesa de Pneumologia, Revista Portuguesa de Pneumologia, (14), p. S9-S20, 2008
DOI: 10.1016/s0873-2159(15)30310-x
Full text: Download
Until 2004, docetaxel in monotherapy was the standard for second-line treatment of non-small cell lung cancer (NSCLC). Pemetrexed (P) has shown similar activity in this setting with a better adverse event profile. In Portugal, it was introduced in October of 2004.